Potential new complication in drug therapy development for amyotrophic lateral sclerosis

References

• Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942–955.
   PubMed Web of Science ®Google Scholar
• Sorarù G, Ermani M, Logroscino G, et al. Natural history of upper motor neuron-dominant ALS. Amyotroph Lateral Scler. 2010;11:424–429.
   PubMed Web of Science ®Google Scholar
• Talbot K. Motor neuron disease: the bare essentials. Pract Neurol. 2009;9:303–309.
   PubMedGoogle Scholar
• Mehta P, Antao V, Kaye W, et al. Prevalence of amyotrophic lateral sclerosis - United States, 2010-2011. MMWR Supplements. 2014;63:1–14.
   PubMedGoogle Scholar
• Chiò A, Logroscino G, Traynor BJ, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41:118–130.
   PubMed Web of Science ®Google Scholar
• Hirtz D, Thurman DJ, Gwinn-Hardy K, et al. How common are the “common” neurologic disorders? Neurology. 2007;68:326–337.
   PubMed Web of Science ®Google Scholar
• Logroscino G, Traynor BJ, Hardiman O, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatr. 2010;81:385–390.
   PubMed Web of Science ®Google Scholar
• Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59–62.
   PubMed Web of Science ®Google Scholar
• Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci. 2006;7:710–723.
   PubMed Web of Science ®Google Scholar
• Yokoseki A, Shiga A, Tan C-F, et al. TDP-43 mutation in familial amyotrophic lateral sclerosis. Ann Neurol. 2008;63:538–542.
   PubMed Web of Science ®Google Scholar
• Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205–1208.
   PubMed Web of Science ®Google Scholar
• Vance C, Rogelj B, Hortobágyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208–1211.
   PubMed Web of Science ®Google Scholar
• Greenway MJ, Andersen PM, Russ C, et al. ANG mutations segregate with familial and “sporadic” amyotrophic lateral sclerosis. Nat Genet. 2006;38:411–413.
   PubMed Web of Science ®Google Scholar
• DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245–256.
   PubMed Web of Science ®Google Scholar
• Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257–268.
   PubMed Web of Science ®Google Scholar
• Miller RG, Mitchell JD, Lyon M, et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:191–206.
   PubMed Web of Science ®Google Scholar
• Kumar DR, Aslinia F, Yale SH, et al. Jean-Martin Charcot: the father of neurology. Clin Med Res. 2011;9:46–49.
   PubMedGoogle Scholar
• Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol. 2009;65(Suppl 1):S3–S9.
   PubMed Web of Science ®Google Scholar
• Bruijn LI. Amyotrophic lateral sclerosis: from disease mechanisms to therapies. BioTechniques. 2002;32:1112, 1114, 1116 passim.
   Web of Science ®Google Scholar
• Strong MJ, Kesavapany S, Pant HC. The pathobiology of amyotrophic lateral sclerosis: a proteinopathy? J Neuropathol Exp Neurol. 2005;64:649–664.
   PubMed Web of Science ®Google Scholar
• Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009;4:3.
   PubMed Web of Science ®Google Scholar
• Martin LJ, Price AC, Kaiser A, et al. Mechanisms for neuronal degeneration in amyotrophic lateral sclerosis and in models of motor neuron death (Review). Int J Mol Med. 2000;5:3–13.
   PubMed Web of Science ®Google Scholar
• Rodrigues MCO, Voltarelli JC, Sanberg PR, et al. Immunological aspects in amyotrophic lateral sclerosis. Transl Stroke Res. 2012;3:331–340.
   PubMed Web of Science ®Google Scholar
• Rodrigues MCO, Sanberg PR, Cruz LE, et al. The innate and adaptive immunological aspects in neurodegenerative diseases. J Neuroimmunol. 2014;269:1–8.
   PubMed Web of Science ®Google Scholar
• McCombe PA, Henderson RD. The role of immune and inflammatory mechanisms in ALS. Curr Mol Med. 2011;11:246–254.
   PubMed Web of Science ®Google Scholar
• D’Amico E, Factor-Litvak P, Santella RM, et al. Clinical perspective on of oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med. 2013;65:509–527.
   PubMed Web of Science ®Google Scholar
• Papadimitriou D, Le Verche V, Jacquier A, et al. Inflammation in ALS and SMA: sorting out the good from the evil. Neurobiol Dis. 2010;37:493–502.
   PubMed Web of Science ®Google Scholar
• Zhao W, Beers DR, Appel SH. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J Neuroimmune Pharmacol. 2013;8:888–899.
   PubMed Web of Science ®Google Scholar
• Calvo AC, Manzano R, Mendonça DMF, et al. Amyotrophic lateral sclerosis: a focus on disease progression. Biomed Res Int. 2014;2014:925101.
   PubMedGoogle Scholar
• Aggarwal S, Cudkowicz M. ALS drug development: reflections from the past and a way forward. Neurotherapeutics. 2008;5:516–527.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Katz J, Moore DH, et al. Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11:259–265.
   PubMed Web of Science ®Google Scholar
• Kalra S, Genge A, Arnold DL. A prospective, randomized, placebo-controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:22–26.
   PubMed Web of Science ®Google Scholar
• Beck M, Flachenecker P, Magnus T, et al. Autonomic dysfunction in ALS: a preliminary study on the effects of intrathecal BDNF. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6:100–103.
   PubMed Web of Science ®Google Scholar
• Miller RG, Petajan JH, Bryan WW, et al. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. Ann Neurol. 1996;39:256–260.
   PubMed Web of Science ®Google Scholar
• Giménez Y, Ribotta M, Revah F, et al. Prevention of motoneuron death by adenovirus-mediated neurotrophic factors. J Neurosci Res. 1997;48:281–285.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Klinkosz B, Greene T, et al. Effects of brain-derived neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease. Ann Neurol. 1995;37:505–511.
   PubMed Web of Science ®Google Scholar
• Sendtner M, Kreutzberg GW, Thoenen H. Ciliary neurotrophic factor prevents the degeneration of motor neurons after axotomy. Nature. 1990;345:440–441.
   PubMed Web of Science ®Google Scholar
• Sendtner M, Schmalbruch H, Stöckli KA, et al. Ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motor neuronopathy. Nature. 1992;358:502–504.
   PubMed Web of Science ®Google Scholar
• Kaspar BK, Lladó J, Sherkat N, et al. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science. 2003;301:839–842.
   PubMed Web of Science ®Google Scholar
• Nagano I, Ilieva H, Shiote M, et al. Therapeutic benefit of intrathecal injection of insulin-like growth factor-1 in a mouse model of amyotrophic lateral sclerosis. J Neurol Sci. 2005;235:61–68.
   PubMed Web of Science ®Google Scholar
• Lepore AC, Haenggeli C, Gasmi M, et al. Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS. Brain Res. 2007;1185:256–265.
   PubMed Web of Science ®Google Scholar
• Dodge JC, Haidet AM, Yang W, et al. Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity. Mol Ther. 2008;16:1056–1064.
   PubMed Web of Science ®Google Scholar
• Messi ML, Clark HM, Prevette DM, et al. The lack of effect of specific overexpression of IGF-1 in the central nervous system or skeletal muscle on pathophysiology in the G93A SOD-1 mouse model of ALS. Exp Neurol. 2007;207:52–63.
   PubMed Web of Science ®Google Scholar
• Franz CK, Federici T, Yang J, et al. Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS. Neurobiol Dis. 2009;33:473–481.
   PubMed Web of Science ®Google Scholar
• Nagano I, Shiote M, Murakami T, et al. Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis. Neurol Res. 2005;27:768–772.
   PubMed Web of Science ®Google Scholar
• Sorenson EJ, Windbank AJ, Mandrekar JN, et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology. 2008;71:1770–1775.
   PubMed Web of Science ®Google Scholar
• Sakowski SA, Schuyler AD, Feldman EL. Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009;10:63–73.
   PubMed Web of Science ®Google Scholar
• Henriques A, Pitzer C, Schneider A. Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand? Front Neurosci. 2010;4:32.
   PubMed Web of Science ®Google Scholar
• Yacila G, Sari Y. Potential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis. Curr Med Chem. 2014;21:3583–3593.
   PubMed Web of Science ®Google Scholar
• Kriz J, Nguyen MD, Julien J-P. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis. 2002;10:268–278.
   PubMed Web of Science ®Google Scholar
• Zhang W, Narayanan M, Friedlander RM. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol. 2003;53:267–270.
   PubMed Web of Science ®Google Scholar
• Van Den Bosch L, Tilkin P, Lemmens G, et al. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport. 2002;13:1067–1070.
   PubMed Web of Science ®Google Scholar
• Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007;6:1045–1053.
   PubMed Web of Science ®Google Scholar
• Gámez J. [Minocycline for the treatment of amyotrophic lateral sclerosis: neuroprotector or neurotoxin? Reflections on another failure of translational medicine]. Neurologia. 2008;23:484–493. Spanish.
   PubMed Web of Science ®Google Scholar
• Keller AF, Gravel M, Kriz J. Treatment with minocycline after disease onset alters astrocyte reactivity and increases microgliosis in SOD1 mutant mice. Exp Neurol. 2011;228:69–79.
   PubMed Web of Science ®Google Scholar
• Groeneveld GJ, Veldink JH, van der Tweel I, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol. 2003;53:437–445.
   PubMed Web of Science ®Google Scholar
• Shefner JM, Cudkowicz ME, Schoenfeld D, et al. A clinical trial of creatine in ALS. Neurology. 2004;63:1656–1661.
   PubMed Web of Science ®Google Scholar
• Rosenfeld J, King RM, Jackson CE, et al. Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS. Amyotroph Lateral Scler. 2008;9:266–272.
   PubMed Web of Science ®Google Scholar
• Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med. 1999;5:347–350.
   PubMed Web of Science ®Google Scholar
• Drachman DB, Frank K, Dykes-Hoberg M, et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol. 2002;52:771–778.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol. 2006;60:22–31.
   PubMed Web of Science ®Google Scholar
• Rothstein JD, Patel S, Regan MR, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005;433:73–77.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Titus S, Kearney M, et al. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13:1083–1091.
   PubMed Web of Science ®Google Scholar
• Wang R, Zhang D. Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. Eur J Neurosci. 2005;22:2376–2380.
   PubMed Web of Science ®Google Scholar
• Joo I-S, Hwang D-H, Seok J-I, et al. Oral administration of memantine prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Clin Neurol. 2007;3:181–186.
   PubMed Web of Science ®Google Scholar
• De Carvalho M, Pinto S, Costa J, et al. A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11:456–460.
   PubMed Web of Science ®Google Scholar
• Levine TD, Bowser R, Hank N, et al. A pilot trial of memantine and riluzole in ALS: correlation to CSF biomarkers. Amyotroph Lateral Scler. 2010;11:514–519.
   PubMed Web of Science ®Google Scholar
• Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol. 1996;39:147–157.
   PubMed Web of Science ®Google Scholar
• Gurney ME, Fleck TJ, Himes CS, et al. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology. 1998;50:62–66.
   PubMed Web of Science ®Google Scholar
• Riviere M, Meininger V, Zeisser P, et al. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol. 1998;55:526–528.
   PubMed Web of Science ®Google Scholar
• Dunlop J, Beal McIlvain H, She Y, et al. Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis. J Neurosci. 2003;23:1688–1696.
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Alexander M, Corr B, et al. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000. J Neurol Neurosurg Psychiatr. 2003;74:1258–1261.
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Beghi E, Palagano G, et al. Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy. Eur J Neurol. 2007;14:262–268.
   PubMed Web of Science ®Google Scholar
• Shefner JM, Wolff AA, Meng L, et al. A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2016;1–10.
   PubMed Web of Science ®Google Scholar
• Hwee DT, Kennedy A, Ryans J, et al. Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model. PLoS ONE. 2014;9:e96921.
   PubMed Web of Science ®Google Scholar
• Ludolph AC, Bendotti C, Blaugrund E, et al. Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop. Amyotroph Lateral Scler. 2007;8:217–223.
   PubMedGoogle Scholar
• Scott S, Kranz JE, Cole J, et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler. 2008;9:4–15.
   PubMed Web of Science ®Google Scholar
• Vincent AM, Sakowski SA, Schuyler A, et al. Strategic approaches to developing drug treatments for ALS. Drug Discov Today. 2008;13:67–72.
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Santamato A, Lamberti P. Current and emerging treatments for amyotrophic lateral sclerosis. Neuropsychiatr Dis Treat. 2009;5:577–595.
   PubMed Web of Science ®Google Scholar
• Bedlack RS, Traynor BJ, Cudkowicz ME. Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007;12:229–252.
   PubMed Web of Science ®Google Scholar
• Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis. 2007;26:1–13.
   PubMed Web of Science ®Google Scholar
• Ludolph AC, Jesse S. Evidence-based drug treatment in amyotrophic lateral sclerosis and upcoming clinical trials. Ther Adv Neurol Disord. 2009;2:319–326.
   PubMedGoogle Scholar
• Carter GT, Krivickas LS, Weydt P, et al. Drug therapy for amyotrophic lateral sclerosis: where are we now? IDrugs. 2003;6:147–153.
   PubMed Web of Science ®Google Scholar
• Siciliano G, Carlesi C, Pasquali L, et al. Clinical trials for neuroprotection in ALS. CNS Neurol Disord Drug Targets. 2010;9:305–313.
   PubMed Web of Science ®Google Scholar
• Wainger BJ, Kiskinis E, Mellin C, et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 2014;7:1–11.
   PubMed Web of Science ®Google Scholar
• Herrando-Grabulosa M, Mulet R, Pujol A, et al. Novel neuroprotective multicomponent therapy for amyotrophic lateral sclerosis designed by networked systems. PLoS ONE. 2016;11:e0147626.
   Web of Science ®Google Scholar
• Ramesh T, Lyon AN, Pineda RH, et al. A genetic model of amyotrophic lateral sclerosis in zebrafish displays phenotypic hallmarks of motoneuron disease. Dis Model Mech. 2010;3:652–662.
   PubMed Web of Science ®Google Scholar
• Ciura S, Lattante S, Le Ber I, et al. Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Ann Neurol. 2013;74:180–187.
   PubMed Web of Science ®Google Scholar
• Patten SA, Parker JA, Wen X-Y, et al. Simple animal models for amyotrophic lateral sclerosis drug discovery. Expert Opin Drug Discov. 2016;1–8.
   Web of Science ®Google Scholar
• Babin PJ, Goizet C, Raldúa D. Zebrafish models of human motor neuron diseases: advantages and limitations. Prog Neurobiol. 2014;118:36–58.
   PubMed Web of Science ®Google Scholar
• Jeong J-Y, Kwon H-B, Ahn J-C, et al. Functional and developmental analysis of the blood-brain barrier in zebrafish. Brain Res Bull. 2008;75:619–628.
   PubMed Web of Science ®Google Scholar
• Eliceiri BP, Gonzalez AM, Baird A. Zebrafish model of the blood-brain barrier: morphological and permeability studies. Methods Mol Biol. 2011;686:371–378.
   PubMedGoogle Scholar
• Fleming A, Diekmann H, Goldsmith P. Functional characterisation of the maturation of the blood-brain barrier in larval zebrafish. PLoS ONE. 2013;8:e77548.
   PubMed Web of Science ®Google Scholar
• Kastin AJ, Akerstrom V, Pan W. Glial cell line-derived neurotrophic factor does not enter normal mouse brain. Neurosci Lett. 2003;340:239–241.
   PubMed Web of Science ®Google Scholar
• Dobrogowska DH, Lossinsky AS, Tarnawski M, et al. Increased blood-brain barrier permeability and endothelial abnormalities induced by vascular endothelial growth factor. J Neurocytol. 1998;27:163–173.
   PubMedGoogle Scholar
• Yang J-P, Liu H-J, Cheng S-M, et al. Direct transport of VEGF from the nasal cavity to brain. Neurosci Lett. 2009;449:108–111.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Blood-brain barrier biology and methodology. J Neurovirol. 1999;5:556–569.
   PubMed Web of Science ®Google Scholar
• Vorbrodt AW, Dobrogowska DH. Molecular anatomy of intercellular junctions in brain endothelial and epithelial barriers: electron microscopist’s view. Brain Res Rev. 2003;42:221–242.
   PubMed Web of Science ®Google Scholar
• Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis. 2004;16:1–13.
   PubMed Web of Science ®Google Scholar
• Engelhardt B. Regulation of immune cell entry into the central nervous system. Results Probl Cell Differ. 2006;43:259–280.
   PubMedGoogle Scholar
• Abbott NJ, Patabendige AAK, Dolman DEM, et al. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37:13–25.
   PubMed Web of Science ®Google Scholar
• Hirase T, Staddon JM, Saitou M, et al. Occludin as a possible determinant of tight junction permeability in endothelial cells. J Cell Sci. 1997;110(Pt 14):1603–1613.
   PubMed Web of Science ®Google Scholar
• Furuse M, Hirase T, Itoh M, et al. Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol. 1993;123:1777–1788.
   PubMed Web of Science ®Google Scholar
• Furuse M, Fujita K, Hiiragi T, et al. Claudin-1 and −2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol. 1998;141:1539–1550.
   PubMed Web of Science ®Google Scholar
• Tsukita S, Furuse M. Overcoming barriers in the study of tight junction functions: from occludin to claudin. Genes Cells. 1998;3:569–573.
   PubMed Web of Science ®Google Scholar
• Rutka JT, Apodaca G, Stern R, et al. The extracellular matrix of the central and peripheral nervous systems: structure and function. J Neurosurg. 1988;69:155–170.
   PubMed Web of Science ®Google Scholar
• Dermietzel R, Krause D. Molecular anatomy of the blood-brain barrier as defined by immunocytochemistry. Int Rev Cytol. 1991;127:57–109.
   PubMed Web of Science ®Google Scholar
• Prat A, Biernacki K, Wosik K, et al. Glial cell influence on the human blood-brain barrier. Glia. 2001;36:145–155.
   PubMed Web of Science ®Google Scholar
• Abbott NJ. Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat. 2002;200:629–638.
   PubMed Web of Science ®Google Scholar
• Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7:41–53.
   PubMed Web of Science ®Google Scholar
• Leonardi A, Abbruzzese G, Arata L, et al. Cerebrospinal fluid (CSF) findings in amyotrophic lateral sclerosis. J Neurol. 1984;231:75–78.
   PubMed Web of Science ®Google Scholar
• Apostolski S, Nikolić J, Bugarski-Prokopljević C, et al. Serum and CSF immunological findings in ALS. Acta Neurol Scand. 1991;83:96–98.
   PubMed Web of Science ®Google Scholar
• Bilic E, Rudan I, Kusec V, et al. Comparison of the growth hormone, IGF-1 and insulin in cerebrospinal fluid and serum between patients with motor neuron disease and healthy controls. Eur J Neurol. 2006;13:1340–1345.
   PubMed Web of Science ®Google Scholar
• Pirttilä T, Vanhatalo S, Turpeinen U, et al. Cerebrospinal fluid insulin-like growth factor-1, insulin growth factor binding protein-2 or nitric oxide are not increased in MS or ALS. Acta Neurol Scand. 2004;109:337–341.
   PubMed Web of Science ®Google Scholar
• Garbuzova-Davis S, Haller E, Saporta S, et al. Ultrastructure of blood-brain barrier and blood-spinal cord barrier in SOD1 mice modeling ALS. Brain Res. 2007;1157:126–137.
   PubMed Web of Science ®Google Scholar
• Garbuzova-Davis S, Saporta S, Haller E, et al. Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALS. PLoS ONE. 2007;2:e1205.
   PubMed Web of Science ®Google Scholar
• Garbuzova-Davis S, Hernandez-Ontiveros DG, Rodrigues MCO, et al. Impaired blood-brain/spinal cord barrier in ALS patients. Brain Res. 2012;1469:114–128.
   PubMed Web of Science ®Google Scholar
• Nicaise C, Mitrecic D, Demetter P, et al. Impaired blood-brain and blood-spinal cord barriers in mutant SOD1-linked ALS rat. Brain Res. 2009;1301:152–162.
   PubMed Web of Science ®Google Scholar
• Zhong Z, Deane R, Ali Z, et al. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci. 2008;11:420–422.
   PubMed Web of Science ®Google Scholar
• Miyazaki K, Ohta Y, Nagai M, et al. Disruption of neurovascular unit prior to motor neuron degeneration in amyotrophic lateral sclerosis. J Neurosci Res. 2011;89:718–728.
   PubMed Web of Science ®Google Scholar
• Henkel JS, Beers DR, Wen S, et al. Decreased mRNA expression of tight junction proteins in lumbar spinal cords of patients with ALS. Neurology. 2009;72:1614–1616.
   PubMed Web of Science ®Google Scholar
• Winkler EA, Sengillo JD, Sullivan JS, et al. Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125:111–120.
   PubMed Web of Science ®Google Scholar
• Garbuzova-Davis S, Rodrigues MCO, Hernandez-Ontiveros DG, et al. Amyotrophic lateral sclerosis: a neurovascular disease. Brain Res. 2011;1398:113–125.
   PubMed Web of Science ®Google Scholar
• Garbuzova-Davis S, Saporta S, Sanberg PR. Implications of blood-brain barrier disruption in ALS. Amyotroph Lateral Scler. 2008;9:375–376.
   PubMed Web of Science ®Google Scholar
• Garbuzova-avis S, Sanberg PR. Blood-CNS barrier impairment in ALS patients versus an animal model. Front Cell Neurosci. 2014;8:21.
   PubMed Web of Science ®Google Scholar
• Rule RR, Schuff N, Miller RG, et al. Gray matter perfusion correlates with disease severity in ALS. Neurology. 2010;74:821–827.
   PubMed Web of Science ®Google Scholar
• Vlasenko A, Garbuzova-Davis S. The role of matrix metalloproteinases in neurovascular unit integrity in amyotrophic lateral sclerosis. Neurol Res Ther Open Access. 2015;2:112–129.
   Google Scholar
• Zwolinski BJ, Eyring H, Reese CE. Diffusion and membrane permeability. J Phys Chem. 1949;53:1426–1453.
   Web of Science ®Google Scholar
• Moreau C, Brunaud-Danel V, Dallongeville J, et al. Modifying effect of arterial hypertension on amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012;13:194–201.
   PubMed Web of Science ®Google Scholar
• Lin F-C, Tsai C-P, Kuang-Wu Lee J, et al. Angiotensin-converting enzyme inhibitors and amyotrophic lateral sclerosis risk: a total population-based case-control study. JAMA Neurol. 2015;72:40–48.
   PubMed Web of Science ®Google Scholar
• Burke M. Why Alzheimer’s drugs keep failing [Internet]. Scientific American; 2014 [cited 2016 Mar 9]. Available from: http://www.scientificamerican.com/article/why-alzheimer-s-drugs-keep-failing/.
   Google Scholar
• Gauthier S, Albert M, Fox N, et al. Why has therapy development for dementia failed in the last two decades? Alzheimers Dement. 2016;12:60–64.
   PubMed Web of Science ®Google Scholar
• Claudio L. Ultrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer’s disease patients. Acta Neuropathol. 1996;91:6–14.
   PubMed Web of Science ®Google Scholar
• Kalaria RN, Pax AB. Increased collagen content of cerebral microvessels in Alzheimer’s disease. Brain Res. 1995;705:349–352.
   PubMed Web of Science ®Google Scholar
• Bourasset F, Ouellet M, Tremblay C, et al. Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer’s disease. Neuropharmacology. 2009;56:808–813.
   PubMed Web of Science ®Google Scholar
• González-Marrero I, Giménez-Llort L, Johanson CE, et al. Choroid plexus dysfunction impairs beta-amyloid clearance in a triple transgenic mouse model of Alzheimer’s disease. Front Cell Neurosci. 2015;9:17.
   PubMed Web of Science ®Google Scholar
• Mehta DC, Short JL, Nicolazzo JA. Altered brain uptake of therapeutics in a triple transgenic mouse model of Alzheimer’s disease. Pharm Res. 2013;30:2868–2879.
   PubMed Web of Science ®Google Scholar
• Trudeau K, Roy S, Guo W, et al. Fenofibric acid reduces fibronectin and collagen type IV overexpression in human retinal pigment epithelial cells grown in conditions mimicking the diabetic milieu: functional implications in retinal permeability. Invest Ophthalmol Vis Sci. 2011;52:6348–6354.
   PubMed Web of Science ®Google Scholar
• Liebetrau M, Burggraf D, Büscher C, et al. Ramipril prevents extracellular matrix accumulation in cerebral microvessels. Neurol Res. 2005;27:477–482.
   PubMed Web of Science ®Google Scholar
• Stichel CC, Hermanns S, Luhmann HJ, et al. Inhibition of collagen IV deposition promotes regeneration of injured CNS axons. Eur J Neurosci. 1999;11:632–646.
   PubMed Web of Science ®Google Scholar